European Journal of Neurology

Calendar
pp. i-i(1)

Instructions for Authors
pp. ii-iii(2)

Intravascular lymphoma presenting with neurological signs but diagnosed by prostate biopsy: suspicion as a key to early diagnosis
pp. e39-e41(3)
Authors: Pusch, G.; Feher, G.; Szomor, A.; Kover, F.; Gomori, E.; Illes, Z.

Late-onset vanishing white matter disease with compound heterozygous EIF2B5 gene mutations
pp. e42-e43(2)
Authors: Lee, H.-N.; Koh, S.-H.; Lee, K.-Y.; Ki, C.-S.; Lee, Y. J.

Joseph Babinski - French neurologist of Polish descent
pp. e44-e44(1)
Authors: Ambrosius, W.; Michalak, S.

Cerebral edema and intracranial hypertension in an adult with maple syrup urine disease
pp. e45-e46(2)
Authors: Sutter, R.; Killer, H. E.; Bilz, S.; Baumgartner, M.; Ott, H. W.; Steck, A. J.; Renaud, S.

Reply to the Letter to the Editor `Cuban Epidemic Optic Neuropathy (CEON) and actual methods to measure immune response in central nervous system'
pp. e47-e47(1)
Authors: González-Quevedo, A.; Suárez Luis, I.; González García, S.; Fernández Carriera, R

Cuban epidemic optic neuropathy (CEOP) and actual methods to measure immune response in CNS
pp. e48-e48(1)
Author: Dorta-Contreras, A. J.

Acute hand weakness as a regional variant of Guillain-Barré syndrome
pp. e49-e49(1)
Authors: Galassi, G.; Girolami, F.; Nobile-Orazio, E.; Funakoshi, K.; Ariatti, A.; Odaka, M.

The Fainting Phenomenon. Understanding why people faint and what to do about it. 2nd edn.
pp. e50-e50(1)
Author: Jellinger, K. A.

Interactive Atlas of the Human Brain
pp. e51-e51(1)
Author: Jellinger, K. A.

Toward Brain-Computer Interfacing
pp. e52-e52(1)
Author: Jellinger, K. A.

Handbook of Clinical Neuroepidemiology
pp. e53-e53(1)
Author: Jellinger, K. A.

Oxford Handbook of Transcranial Stimulation
pp. e54-e54(1)
Author: Jellinger, K. A.

Greenfield's Neuropathology, 8th edition
pp. e55-e56(2)
Author: Jellinger, K. A.

The Confabulating Mind How the brain creates reality
pp. e57-e57(1)
Author: Jellinger, K. A.

Parkinson's Disease and Other Movement Disorders
pp. e58-e58(1)
Author: Jellinger, K. A.

A Theory of the Basal Ganglia and Their Disorders
pp. e59-e59(1)
Author: Jellinger, K. A.

A Neurodynamic Theory of Schizophrenia (and Related Disorders)
pp. e60-e60(1)
Author: Jellinger, K. A.

Textbook of Epilepsy Surgery
pp. e61-e61(1)
Author: Jellinger, K. A.

Neurologic Complications of Cancer, Second edition
pp. e62-e62(1)
Author: Jellinger, K. A.

Headache Simplified
pp. e63-e63(1)
Author: Jellinger, K. A.

Disorders of Consciousness Handbook of Clinical Neurology, Volume 90, 3rd Series
pp. e64-e64(1)
Author: Jellinger, K. A.

Practical Neurology, 3rd edn
pp. e65-e65(1)
Author: Jellinger, K. A.

Stroke Part I: Basic and Epidemiological Aspects
pp. e66-e66(1)
Author: Jellinger, K. A.

Stroke Part II: Clinical Manifestations and Pathogenesis - Handbook of Clinical Neurology, vol. 93 (3rd Series)
pp. e67-e67(1)
Author: Jellinger, K. A.

Stroke Part III: Investigations and Management, Handbook of clinical Neurology vol. 94 (3rd Series)
pp. e68-e68(1)
Author: Jellinger, K. A.

Neurotropic Virus Infections
pp. e69-e69(1)
Author: Jellinger, K. A.

Cerebral autoregulation impairment during wakefulness in obstructive sleep apnea syndrome is a potential mechanism increasing stroke risk
pp. 283-284(2)
Authors: Tsivgoulis, G.; Alexandrov, A. V.

Long-term treatment outcome with different formulations of botulinum toxin
pp. 285-286(2)
Authors: Pérez-Saldaña, M. T.; Tan, E. K.; Burguera, J. A.

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?
pp. 287-288(2)
Author: Sorensen, P. S.

Spinal cord sarcoidosis: report of seven cases
pp. 289-296(8)
Authors: Varron, L.; Broussolle, C.; Candessanche, J.-P.; Marignier, R.; Rousset, H.; Ninet, J.; Sève, P.

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options
pp. 297-309(13)
Authors: Ludolph, A. C.; Kassubek, J.; Landwehrmeyer, B. G.; Mandelkow, E.; Mandelkow, E.-M.; Burn, D. J.; Caparros-Lefebvre, D.; Frey, K. A.; de Yebenes, J. G.; Gasser, T.; Heutink, P.; Höglinger, G.; Jamrozik, Z.; Jellinger, K. A.; Kazantsev, A.; Kretzschmar, H.; Lang, A. E.; Litvan, I.; Lucas, J. J.; McGeer, P. L.; Melquist, S.; Oertel, W.; Otto, M.; Paviour, D.; Reum, T.; Saint-Raymond, A.; Steele, J. C.; Tolnay, M.; Tumani, H.; van Swieten, J. C.; Vanier, M. T.; Vonsattel, J.-P.; Wagner, S.; Wszolek, Z. K.

Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese
pp. 310-316(7)
Authors: Chan, K. H.; Ramsden, D. B.; Yu, Y. L.; Kwok, K. H. H.; Chu, A. C. Y.; Ho, P. W. L.; Kwan, J. S. C.; Lee, R.; Lim, E.; Kung, M. H. W.; Ho, S. L.

Disrupted sleep and circadian patterns in frontotemporal dementia
pp. 317-323(7)
Authors: Anderson, K. N.; Hatfield, C.; Kipps, C.; Hastings, M.; Hodges, J. R.

Dijon's vanishing lead with regard to low incidence of stroke
pp. 324-329(6)
Authors: Béjot, Y.; Osseby, G. V.; Aboa-éboulé, C.; Durier, J.; Lorgis, L.; Cottin, Y.; Moreau, T.; Giroud, M.

Population-based case-control study of morale in Parkinson's disease
pp. 330-336(7)
Authors: Benito-León, J.; Louis, E. D.; Bermejo-Pareja, F.

Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families
pp. 337-341(5)
Authors: Saporta, M. A. C.; Zaros, C.; Cruz, M. W.; André, C.; Misrahi, M.; Bonaïti-Pellié, C.; Planté-Bordeneuve, V.

Age of puberty and the risk of multiple sclerosis: a population based study
pp. 342-347(6)
Authors: Ramagopalan, S. V.; Valdar, W.; Criscuoli, M.; DeLuca, G. C.; Dyment, D. A.; Orton, S.-M.; Yee, I. M.; Ebers, G. C.; Sadovnick, A. D.

Fatigue, depression and disability accumulation in multiple sclerosis: a cross-sectional study
pp. 348-352(5)
Authors: Koch, M.; Mostert, J.; Heerings, M.; Uyttenboogaart, M.; De Keyser, J.

Measuring function in advanced ALS: validation of ALSFRS-EX extension items
pp. 353-359(7)
Authors: Wicks, P.; Massagli, M. P.; Wolf, C.; Heywood, J.

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study
pp. 360-366(7)
Authors: Rossi, S.; Mataluni, G.; Codecà, C.; Fiore, S.; Buttari, F.; Musella, A.; Castelli, M.; Bernardi, G.; Centonze, D.

Does the menstrual cycle influence the motor and phosphene thresholds in migraine?
pp. 367-374(8)
Authors: Boros, K.; Poreisz, C.; Paulus, W.; Antal, A.

Femoral nerve involvement in diabetics
pp. 375-379(5)
Authors: Kurt, S.; Kaplan, Y.; Karaer, H.; Erkorkmaz, U.

Multiple sclerosis patients with anti-lipid oligoclonal IgM show early favourable response to immunomodulatory treatment
pp. 380-385(6)
Authors: García-Barragán, N.; Villar, L. M.; Espiño, M.; Sádaba, M. C.; González-Porqué, P.; Álvarez-Cermeño, J. C.

Cerebral autoregulation in patients with obstructive sleep apnea syndrome during wakefulness
pp. 386-391(6)
Authors: Nasr, N.; Traon, A. Pavy-Le; Czosnyka, M.; Tiberge, M.; Schmidt, E.; Larrue, V.

Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm
pp. 392-398(7)
Authors: Bentivoglio, A. R.; Fasano, A.; Ialongo, T.; Soleti, F.; Lo Fermo, S.; Albanese, A.

Detection and analysis of Borna disease virus in Chinese patients with neurological disorders
pp. 399-403(5)
Authors: Li, Q.; Wang, Z.; Zhu, D.; Xu, M.; Chen, X.; Peng, D.; Iwata, Y.; Xie, P.

One-year follow up of patients with chronic tinnitus treated with left temporoparietal rTMS
pp. 404-408(5)
Authors: Khedr, E. M.; Rothwell, J. C.; El-Atar, A.

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis
pp. 409-412(4)
Authors: Kopadze, T.; Döbert, M.; Leussink, V. I.; Dehmel, T.; Kieseier, B. C.

Lack of association of hormone receptor polymorphisms with migraine
pp. 413-415(3)
Authors: Corominas, R.; Ribasés, M.; Cuenca-León, E.; Cormand, B.; Macaya, A.

Predictive value of clinical characteristics in patients with suspected cauda equina syndrome
pp. 416-419(4)
Authors: Domen, P. M.; Hofman, P. A.; van Santbrink, H.; Weber, W. E. J.

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study
pp. 420-423(4)
Authors: Oturai, A. B.; Koch-Henriksen, N.; Petersen, T.; Jensen, P. E. H.; Sellebjerg, F.; Sorensen, P. S.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
pp. 424-426(3)
Authors: Putzki, N.; Kollia, K.; Woods, S.; Igwe, E.; Diener, H. C.; Limmroth, V.

HLA-DRB1 and multiple sclerosis in Argentina
pp. 427-429(3)
Authors: Patrucco, L.; Larriba, J.; Redal, M. A.; Rojas, J. I.; Argibay, P. F.; Cristiano, E.

Unilateral RLS with predominantly ipsilateral PLMS and variable response to dopaminergic drugs: a variant of idiopathic RLS?
pp. 430-432(3)
Authors: Valko, P. O.; Siccoli, M. M.; Bassetti, C. L.